Abbott Laboratories (NYSE:ABT) Shares Sold by Graypoint LLC

Graypoint LLC lowered its holdings in Abbott Laboratories (NYSE:ABTFree Report) by 4.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,718 shares of the healthcare product maker’s stock after selling 2,398 shares during the quarter. Graypoint LLC’s holdings in Abbott Laboratories were worth $5,472,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Halpern Financial Inc. acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth $26,000. Altshuler Shaham Ltd acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $28,000. Cornerstone Planning Group LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth $28,000. CGC Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth $32,000. Finally, FWL Investment Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at approximately $9,444,480. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,435 shares of company stock valued at $6,451,298. Corporate insiders own 1.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $128.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Raymond James lifted their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Barclays lifted their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Citigroup lifted their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $122.14.

Check Out Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $109.11 on Friday. The stock’s 50 day moving average price is $114.72 and its 200 day moving average price is $107.36. The firm has a market capitalization of $189.33 billion, a PE ratio of 33.47, a price-to-earnings-growth ratio of 2.63 and a beta of 0.74. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last released its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, hitting the consensus estimate of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The firm had revenue of $10.24 billion for the quarter, compared to analyst estimates of $10.19 billion. During the same period in the previous year, the company posted $1.03 EPS. Abbott Laboratories’s revenue for the quarter was up 1.5% on a year-over-year basis. As a group, sell-side analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.02%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is currently 67.48%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.